In conclusion, these results introduced a new mechanism for Shp2 oncogenic action and shed new light on extranuclear ER-initiated action in breast tumorigenesis by identifying a novel associated protein, Shp2, for this pathway, which might benefit the therapy of breast cancer. The gene discussed is ESR1; the disease is breast carcinoma.